ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 171 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2019. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,966,000 | +512.5% | 14,202 | +88.8% | 0.21% | +583.9% |
| Q4 2019 | $321,000 | -25.7% | 7,521 | +20.7% | 0.03% | +29.2% |
| Q1 2019 | $432,000 | -71.2% | 6,229 | -68.2% | 0.02% | -73.9% |
| Q3 2018 | $1,498,000 | +427.5% | 19,617 | +430.9% | 0.09% | +607.7% |
| Q2 2018 | $284,000 | -17.0% | 3,695 | -49.9% | 0.01% | -27.8% |
| Q4 2017 | $342,000 | – | 7,372 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |